Return to warmwell.com

Fort Dodge Animal Health

Division of Wyeth

Huizerstraatweg 117

1411 GM NAARDEN

The Netherlands




NEWS RELEASE


24 June 2008



Fort Dodge Starts to Supply Bluetongue Serotype 8 Vaccine in Italy


B


OLOGNA, Italia (Giugno 2008) - Fort Dodge Animal Health, a division of Wyeth (NYSE: WYE), has announced the supply of the first 500,000 doses of the Company's Zulvac® 8 vaccine to protect cattle against Bluetongue Serotype 8 disease.  Bluetongue Serotype 8 was first identified in Italy in Mach 2008 in the province of Verona.  Fort Dodge is one of two companies appointed by the Italian government to produce the Bluetongue Serotype 8 vaccine and will supply a total of 4.4 million doses during June and July.


The Ministry of Health has decided to implement a plan of mass vaccination against Bluetongue of bovine animals (Bluetongue) starting with the province of Verona, followed by Mantova and Brescia, and then extending to cover all sensitive cattle in the North of Italy.  The management of the vaccine distribution process will be carried out by the Istituto Zooprofilatico delle Venezie.  Fort Dodge is first company to supply the Serotype 8 vaccine in Italy.  It is being produced at the company's manufacturing facilities in Weesp, The Nederlands.

 

“Because of the challenges that Bluetongue is causing to farmers, Fort Dodge has committed considerable efforts and resources into developing a vaccine," says Stefan Mihailov, General Manager, Fort Dodge Italy.  "We are delighted to be able to support the Italian authorities in bringing outbreaks of Bluetongue in the country under control.”


In addition to supplying the vaccine, Fort Dodge is also providing Renegade insecticide, which is proven to aid in the control of Culicoides spp., the vector of the disease.

 

"We will continue to support farmers in their fight against Bluetongue," comments Marc Snacken, Livestock Manager at Fort Dodge EMEA.  "In addition to our vaccine against Serotype 8 which has now spread widely spread in Europe, we also have a vaccine available to fight Serotype 1, which is proving an increasing problem right across Europe.  We also offer a vaccine against Serotype 4, which is found mainly among sheep in Spain and Italy.”



Note to editors:

Fort Dodge Animal Health, a division of Wyeth, is a leading manufacturer and marketer of products for large and small animals. Key products include Cydectin® cattle and sheep wormer; Equest® horse wormer; GuardianSR® heartworm injection and a range of poultry and pig vaccines.


The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.


These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialisation (including with respect to our pipeline products), drug pricing and payment for our products by government and third-party payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption “Item 1A, RISK FACTORS.” We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.



For further information:

Rebecca George

George PR

Tel: 01449 737281/07974 161108